MMP2 and rheumatoid arthritis: In vitro drug release tests indicated that 90% of CUR was released from the nano-based formulation within 12 h, in the presence of the matrix metalloproteinase-2, suggesting that the formulation could effectively release CUR in the inflamed joints of RA patients, where such a marker is highly expressed.